These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24913498)

  • 21. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
    Lucijanic M; Jaksic O
    Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
    [No Abstract]   [Full Text] [Related]  

  • 22. Bendamustine-induced nephrogenic diabetes insipidus
.
    Derman BA; Jain M; McAninch EA; Gashti C
    Clin Nephrol; 2017 Jan; 87 (2017)(1):47-50. PubMed ID: 27719738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxoplasmosis in patients with hematologic malignancies.
    Chintakuntlawar A; Kidd M; Al-Kali A; Wilson W; Thompson CA
    Leuk Lymphoma; 2015 Feb; 56(2):536-8. PubMed ID: 24882256
    [No Abstract]   [Full Text] [Related]  

  • 24. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Gentile M; Shanafelt TD; Reda G; Mauro FR; Zirlik K; Ciolli S; Laurenti L; Del Principe MI; Rossi D; Di Renzo N; Molica S; Angrilli F; Coscia M; Chiarenza A; Giordano A; Cutrona G; Chaffee KG; Parikh SA; Uccello G; Innocenti I; Tripepi G; D'Arrigo G; Vigna E; Recchia AG; Herishanu Y; Shvidel L; Tadmor T; Cortelezzi A; Del Poeta G; Gaidano G; Di Raimondo F; Neri A; Ferrarini M; Foà R; Polliack A; Morabito F
    Leukemia; 2018 Aug; 32(8):1869-1873. PubMed ID: 29588545
    [No Abstract]   [Full Text] [Related]  

  • 25. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
    Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
    Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
    [No Abstract]   [Full Text] [Related]  

  • 26. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended follow-up of CD4
    Gaiolla R; Hartley S; Beech A; Knight H; Smith D; Bishton M; Fox CP; Martinez-Calle N
    Hematol Oncol; 2021 Feb; 39(1):137-140. PubMed ID: 32860715
    [No Abstract]   [Full Text] [Related]  

  • 28. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.
    Fallon MJ; Heck JN
    J Oncol Pharm Pract; 2015 Oct; 21(5):388-92. PubMed ID: 25005569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
    Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
    Vahdani K; Thaung C; Rose GE
    Ophthalmology; 2021 Mar; 128(3):402. PubMed ID: 33612166
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Soumerai JD; Davids MS; Werner L; Fisher DC; Armand P; Amrein PC; Neuberg D; Hochberg EP; Brown JR; Abramson JS
    Leuk Lymphoma; 2019 Dec; 60(12):2931-2938. PubMed ID: 31074316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
    Eren R; Suyanı E
    Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
    [No Abstract]   [Full Text] [Related]  

  • 34. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
    Gomez A; Hoffman JE
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
    Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
    [No Abstract]   [Full Text] [Related]  

  • 38. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
    Fürstenau M; Hopfinger G; Robrecht S; Fink AM; Al-Sawaf O; Langerbeins P; Cramer P; Tresckow JV; Maurer C; Kutsch N; Hoechstetter M; Dreyling M; Lange E; Kneba M; Stilgenbauer S; Döhner H; Hensel M; Kiehl MG; Jaeger U; Wendtner CM; Goede V; Fischer K; von Bergwelt-Baildon M; Eichhorst B; Hallek M; Theurich S
    Leukemia; 2020 Apr; 34(4):1177-1181. PubMed ID: 31728057
    [No Abstract]   [Full Text] [Related]  

  • 40. Lichenoid drug eruption associated with Bendamustine.
    Kusano Y; Terui Y; Yokoyama M; Hatake K
    Blood Cancer J; 2016 Jun; 6(6):e438. PubMed ID: 27341077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.